OXCARBAZEPINE | A213369 | APOTEX INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D.N.J. | 2022-01-24 | Terminated 2022-08-01 | — | |
| D.N.J. | 2020-06-26 | Terminated 2023-06-27 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$10.06
per ea
Lowest NADAC/Unit
$3.70
per ea
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 60505413007OXCARBAZEPINE ER 600 MG TABLET | $10.06 | EA | Generic | — | 2026-06-17 |
| 60505412907OXCARBAZEPINE ER 300 MG TABLET | $4.57 | EA | Generic | — | 2026-06-17 |
| 60505412807OXCARBAZEPINE ER 150 MG TABLET | $3.70 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.